Drug Trial Radar · NCT07748624
A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Dec 26, 2028
Study completion Apr 15, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome. In addition, the study will evaluate the long-term efficacy, safety and tolerability of arumakimig in this population.
Conditions
- VEXAS Syndrome
Interventions
ArumakimigDrug
Arumakimig Injection
PlaceboDrug
Placebo Injection
Oral glucocorticoidsDrug
Background therapy with glucocorticoids. After the first 2 weeks of the study, participants may begin with glucocorticoid tapering depending on the disease status and the Investigator's judgement.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants achieving improvement of key VEXAS manifestations and oral glucocorticoid (GC) reduction at Week 52Time frame: From baseline up to Week 52
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Fukushima, Japan · Recruiting
Novartis Investigative Site
Niigata, Japan · Recruiting
Novartis Investigative Site
Yokohama, Kanagawa, Japan · Recruiting
Novartis Investigative Site
Suita, Osaka, Japan · Recruiting
Novartis Investigative Site
Hachiōji, Tokyo, Japan · Recruiting
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.